Skip to main content
Jacobio Pharmaceuticals Group Co., Ltd. logo

Jacobio Pharmaceuticals Group Co., Ltd. — Investor Relations & Filings

Ticker · 1167 HKEX Manufacturing
Open in API
Filings indexed 298 across all filing types
Latest filing 2025-09-03 Regulatory Filings
Country HK Hong Kong
Listing HKEX 1167

About Jacobio Pharmaceuticals Group Co., Ltd.

http://www.jacobiopharma.com

Jacobio Pharmaceuticals Group Co., Ltd. is a biopharmaceutical company specializing in the in-house discovery and development of innovative oncology therapies. The company is committed to providing breakthrough treatment solutions for patients by focusing its research and development pipeline on six major tumor signaling pathways: KRAS, Tumor Immunity, Tumor Metabolism, P53, RB, and MYC. Jacobio utilizes advanced drug discovery platforms, including induced allosteric mechanisms, to develop novel and improved medicines. The company primarily focuses on developing new drugs at the clinical stage, with the strategic goal of positioning its core projects among the top three globally in their respective therapeutic areas.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 August 2025
Regulatory Filings Classification · 1% confidence The document is a HKEX Form FF301 “Monthly Return for Equity Issuer and Hong Kong Depositary Receipts” under Chapter 19B of the Exchange Listing Rules, detailing monthly movements in authorised/issued share capital and treasury shares. It is a routine regulatory filing under Hong Kong listing requirements rather than an earnings release, annual/interim report, or specific corporate action announcement. It therefore falls into the “Regulatory Filings” fallback category.
2025-09-03 English
TERMS OF REFERENCE OF THE NOMINATION COMMITTEE
Governance Information Classification · 1% confidence The document is the Terms of Reference for the Nomination Committee of the Board, detailing committee composition, duties, authority, procedures, and governance practices. It is not an announcement of a vote or report publication, nor a financial or legal filing, but rather a governance charter outlining internal rules and board structure. This aligns directly with the Governance Information category.
2025-08-29 English
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025
Interim / Quarterly Report Classification · 1% confidence The document is an 'INTERIM RESULTS ANNOUNCEMENT' for the six months ended June 30, 2025, for Jacobio Pharmaceuticals Group Co., Ltd. It contains detailed financial highlights (revenue, R&D expenses, administrative expenses, and loss for the period), a comprehensive management discussion and analysis (MDA), and a detailed status report on the company's drug pipeline. While it is an announcement, it provides substantive financial data and operational analysis for an interim period, fitting the definition of an Interim/Quarterly Report (IR). H2 2025
2025-08-29 English
DATE OF BOARD MEETING
Report Publication Announcement Classification · 1% confidence The document is an announcement by the board of directors of JACOBIO PHARMACEUTICALS GROUP CO., LTD. scheduling a board meeting to consider, approve, and publish the interim results for the six months ended June 30, 2025. It does not contain the interim report itself but informs investors of the timing of its approval and publication. This matches the definition of a Report Publication Announcement (RPA).
2025-08-19 English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 July 2025
Regulatory Filings Classification · 1% confidence The document is an HKEX Form FF301 monthly return detailing movements in authorized share capital, issued shares, treasury shares, and repurchase transactions for the month ended 31 July 2025. It is a routine periodic regulatory submission under the Listing Rules rather than an earnings release, management commentary, AGM material, or capital financing document. No other more specific category applies, so it falls into the general regulatory filings fallback category.
2025-08-04 English
VOLUNTARY ANNOUNCEMENT FURTHER INCREASE SHAREHOLDINGS OF THE PARTIES ACTING IN CONCERT
Major Shareholding Notification Classification · 1% confidence The announcement details an increase in shareholdings by parties acting in concert, specifying the number of shares purchased, the resulting total stake (25.36%), and compliance with regulatory requirements. This fits the definition of a Major Shareholding Notification (MRQ) rather than a company buyback or other corporate action.
2025-07-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.